Submit the form below to share the content on this site with a friend or colleague.
All fields are required
KADCYLA may be an appropriate treatment option for patients with HER2+ advanced (metastatic) breast cancer that has already been treated with Herceptin® (trastuzumab) and a taxane.
KADCYLA is given alone, and is made up of 2 cancer-fighting drugs in one:
KADCYLA is the first targeted treatment of its kind for HER2+ metastatic breast cancer. Learn more at KADCYLA.com.
Every person who has HER2+ breast cancer is unique, and no cancer treatment works the same for everyone. Talk to your healthcare team for more information about treatment with KADCYLA.
KADCYLA is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
KADCYLA is not the same medicine as trastuzumab (Herceptin).
Contact your doctor right away if you experience symptoms associated with these side effects.
Not all people have serious side effects; however, side effects with KADCYLA treatment are common. It is important to know what side effects may happen and what symptoms you should watch for.
Low platelet count
Skin reactions around the infusion site
You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been shown only in patients whose tumors are HER2-positive.
The most common severe side effects of KADCYLA are:
The most common side effects seen in people taking KADCYLA were: